新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 诺华 » 爱诺华公司获得新型类风湿关节炎生物标记物

爱诺华公司获得新型类风湿关节炎生物标记物

来源:生物谷 2013-10-31 21:28

2013年10月31日讯 /生物谷BIOON/ --类风湿性关节炎是时间上最常见的几种疾病之一,这种疾病给患者带来极大的痛苦并且治愈起来十分困难。而现在通用的生物标记物如heumatoid factor (RF) 以及 anti-cyclic citrullinated peptides (CCP)等并不能100%在患者患病早期检测出异常。现在爱诺华公司从荷兰Hasselt University获得了一种免疫抗体生物标记物能够作为新型类风湿性关节炎检测工具。研究人员在研究中首先选取了一些无法被RF、CCP检测出来的类风湿性关节炎患者,并用自己研发的14种新型标记物进行测试,结果表明这些患者至少会对一种新生物标记物产生反应。Inova诊断公司CEO表示这一研究结果将对类风湿性关节炎治疗和预测起到重要推动作用。(生物谷Bioon.com)

详细英文报道:

Inova Diagnostics this week bagged new technology developed at Hasselt University designed to identify a more sensitive collection of biomarkers for rheumatoid arthritis, once again setting its sights on early diagnosis of the debilitating condition.

Researchers at Hasselt, a Dutch institution, demonstrated a need for new biomarkers in the RA arena when studies showed that about a third of patients with the disease tested negative for the two standard serological markers: rheumatoid factor (RF) and anti-cyclic citrullinated peptides (CCP). Their search for new markers led to the identification of 14 new autoantibodies and a 19% increase in sensitivity compared with the current testing methods, according to an Inova release.

In the study, 52% of RA patients who had already tested negative for the disease showed the presence of at least one of the 14 new targets. And 5 of the new autoantibodies had an especially frequent presence in seronegative patients. VIB, a Flemish research institute, helped the university patent the new markers and negotiate the license.

San Diego-based Inova is a leader in the autoimmune field, particularly in the detection of autoantibodies in the blood serum. The diagnostics company, which early this year licensed RA biomarker technology developed at the Leiden University Medical Center, did not disclose the terms of the Hasselt deal.

"Delaying diagnosis of RA can impact the quality of affected patients," said Inova Vice President of R&D Michael Mahler in a statement. "New biomarkers can aid in achieving better outcomes based on appropriate treatment at an earlier stage of this debilitating disease. We believe that the markers identified by the world class immunology researchers at Hasselt University, combined with the assay development expertise at Inova Diagnostics, should result in enhanced capability to accurately diagnose RA patients who are seronegative by existing markers."

The RA diagnosis arena has this year already shown to be of growing interest to investors. In January, Crescendo Bioscience collected $28 million to further commercialize its molecular blood test designed to detect 12 different biomarkers associated with the disease.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库